

FSN Ref:FSN_09%NaCIPFS_NL_05Feb2021 FSCA_Ref: FSCA_09%NaCIPFS_NL_05Feb2021

Date: 05-02-2021

<u>Urgent Field Safety Notice</u> <u>Steriflush® Prefilled 0.9% Sodium Chloride Syringes and Procedure</u> <u>Packs Containing Steriflush® Prefilled 0.9% Sodium Chloride</u> <u>Syringes</u>

For Attent ion of*:End User

Contact details of local representative (name, e-mail, telephone, address etc.)*

Liber Medical BV

Bergseweg 4, 3633 AK Vreeland

Ultrecht

0294 764 101



(FSN)

Steriflush® Prefilled 0.9% Sodium Chloride Syringes and Procedure Packs Containing Steriflush® Prefilled 0.9% Sodium Chloride

S;vrmaes

1 Inf	ormation on Affected Devi	Ces*
1. Device Type(s)*	ormation on Anotted Bovi	000
Syringe NaCl 0,9% Luer Loek	20 ml *S	
2. Commercial name(s)	20 1111 3	
Prefilled svrinçies 0,9 % sodium	chloride	
3. Unique Device Identifier(s) (UDI-DI)	
5608120PFSNACL0.9L-2P2	,	
4. Primarv clinical purpose	of device(s)*	
The Sterisets Saline 0.9% NaCl	syringes are intended tor flushing	of intravascular catheters,
maintain the patency of indwelli		
Device Model/Catalogue	/part number(s)*	
N/A		
6. Software version		
N/A		
7. Affected serial or lot num	ber range	
Manufacturer's Product Reference	Product Name	LOT
Number	Floductivallie	<u>LOT</u>
14363SAL	Syringe NaCl 0,9% Luer Loek	
	10 ml	
14360S	Syringe 3 ml with 0,9%	
	sodium chloride sterile	
14361S	Syringe 5 ml with 0,9%	
	sodium chloride (3ml fill) sterile	
14366S	Syringe 10 ml with 0,9%	
143003	sodium chloride (5ml fill)	
	sterile	
14362S	Syringe 5 ml with 0,9%	
	sodium chloride	
14363S	Syringe 10 ml with 0,9%	
	sodium chloride	
14364S	Syringe 20 ml with 0,9%	Batch numbers up unt 1809XXX (batch numbe is YYMM123)
	sodium chloride	
TP-50-10	Prefilled syringes 0,9%	
14262CNICAI	Natriumchloride(0,9%NaCl)	
14363SNSAL	Syringe NaCl 0,9% Luer Loek 10 ml	
14365SNSF	Syringe LL 10 ml NaCl 0,9%	
	(3ml fill) sterile White Cap	
14360SNS	Syringe 3 ml with 0,9%	
	sodium chloride sterile/non	
	sterile	
14361SNS	Syringe 5 ml with 0,9%	
	sodium chloride (3ml fill) sterile/non	
	sterile	

Syringe 5 ml with 0,9% sodium chloride sterile/non sterile Syringe 10 ml with 0,9%

sodium chloride sterile/non

14362SNS

14363SNS



N/A

	sterile
14364SNS	Syringe 20 ml with 0,9%
	sodium chloride sterile/non
	sterile
14365SNS	Syringe 10 ml with 0,9% sodium chloride (3ml fill) sterile/non sterile
14366SNS	Syringe 10 ml with 0,9% sodium chloride (5ml fill) sterile/non sterile
100470	Na-und Abschluss-Set /
	homepump
10606912	Dialysis fistel saet
10606914	Haemodialyse start-stop saet
10606902	Aansluitset Dialyse
10606913	Dialyse aansluitset
10606901	Afsluitset dialyse
10606911	Disconnection set dialysis
	home care incl. Flushing
	saline
10609006	Oncology set
10601030	Port Skiftesaet
10609007	Connectionset oncologie
10605810	Picc-line saet
8. Associated devices	



N/A

Reason for Field Safetv Corrective Action (FSCA)* 1. Description of the product problem* Unlikely presence (<0,1%) of trace metals in the syringe stopper used in Steriflush® Prefilled 0.9% Sodium Chloride Svringes, which could potentially generate extremely small brown oarticles. 2. Hazard qivinq rise to the FSCA* N/A Probability of problem arisina Possible to occur - however, the risk is being mitigated to Improbable. Predicted risk to oatienUusers No serieus injuries and or death could occur due to the failure mode associated with this. Further information to help characterise the oroblem N/A 6. Background on Issue Brown particles have been found inside the prefilled syringe containing 0.9%NaCl. After investigation we can conclude that there was an interaction between the sodium chloride 0.9% and the trace metals present in the rubber stopper. The health risk associated with this issue is small as no incident or oatient safety has ever been involved. 7. Other information relevant to FSCA



3. Type of Action to mitigate the risk*				
1. Action To Be Taken by the User*				
	☐ Identify Device ☐ Qua	arantine Device Return D	Device	
	☐ On-site device modification/inspection			
D Follow patient management recommendations				
☐ Take note of amendment/reinforcement of Instructions For Use (IFU)				
	☐ Other ☐ Nor	ne		
2.	By when should the action be completed? 05-03-2021	Specify where critical	a! to patient/end user safety	
Particular considerations for: Choose an item.				
Is follow-up of patients or review of patients' previous results recommended? No Provide further details of patient-level follow-up if required or a justification why none is				
required 4. Is customer Reply Required? * Yes				
(If yes, form attached specifying deadline for return) 05-03-2021				
5.	Action Being Taken by the	Manufacturer		
Product Removal D On-site device modification/inspection D Software upgrade ☐ IFU or labelling change ☐ Other - Provide further details of the action(s) identified. ☐ None				
Eg how the manufacturer became aware; brief details of relevant incidents; root cause if known; rationale for containment of problem to only affected devices; other risk mitigation or langer-term preventative action etc.				
6.	By when should the action be completed?05-03-2021	Specify where critical to pati	ent/end user safety	
7.	Is the FSN required to be couser?	ommunicated to the patient /lay	No	
8.		vided additional information suitable nal user information letter/sheet?	for the patient/lay user in a	



4. General Information*		
1. FSN Type*	New	
2. For updated FSN, reference number and date of orevious FSN 3. For Updated FSN, key new information	N/A	
	e. It is necessary to destroy the syringes with presence	
Further advice or information already expected in follow-up FSN? *	No	
5. If follow-up FSN expected, what is the	further advice expected to relate to:	
6. Anticipated timescale for follow-up FSN	FINAL actions completed	
7. Manufacturer information (For contact details of local representative refer to page 1 of this FSNJ Steripack S.A Only necessary if not evident on letter-head.		
Zona Industrial 1, Lote 11 a 14 4560-164 Guilhufe, Penafiel Portuaal	Only necessary if not evident on letter-head.	
	Only necessary if not evident on letter-head.	
The Competent (Regulatory) Authorit communication to customers. * yes	ty of your country has been informed about this	
9. List of attachments/appendices:	If extensive consider providing web-link instead.	
10. Name/Signature		

Transmission of this Field Safet Notice	
N/A	

Note: Fields indicated by * are considered necessary for all FSNs. Others are optional.



Contact manufacturer

Steripack S.A
Att.:
Zona Industrial 1, Lote 11 a 14
4560-164 Guilhufe, Penafiel
Portugal
Tel.: +351 255 711 355
Fax: +351 255 711 357
Web site: www.sterisets.eu
E-mail:
Acknowledgment of receipt
Sterisets Medical Products requires an acknowledgment of receipt of this notice.
otonote medical reducto requires an actinomoughlone or recorpt of the house.
With regards,
Steripack S.A